Browse the evidence

In well-trained males, the time course of recovery (muscle damage and performance fatigue) following volume-type resistance training (4 sets to failure at 80% 1RM) is similar for the back squat, bench press, and deadlift, refuting the belief that the deadlift requires significantly longer recovery.

If you are a well-trained male, you do not need to schedule significantly more rest days between deadlift sessions compared to squat or bench press sessions, provided you are doing similar volume (e.g., 4 sets to failure at 80% 1RM). You can likely train these movements with similar frequency (e.g., 2-3 times per week) without one causing disproportionately longer fatigue than the others.

GLP-1 analogs and SGLT-2 inhibitors are promising therapeutic modalities for the obese-diabetic phenotype of HFpEF, with GLP-1 analogs showing significant reduction in epicardial adipose tissue (EAT) and body weight.

Newer diabetes drugs (GLP-1s and SGLT-2 inhibitors) are highly effective for obese HFpEF patients. They help lose weight, reduce heart fat (EAT), and improve heart function. GLP-1s like semaglutide can lead to substantial weight loss (up to 10% or more).

Triple agonists (GLP-1/GIP/Glucagon) like retatrutide achieve even greater weight loss (>24%) than dual agonists, likely due to the addition of glucagon receptor agonism which increases energy expenditure.

Triple-agonist injections like retatrutide (12 mg/week) are showing even higher weight loss rates (~24%) than current dual agonists in early trials. This is due to the addition of glucagon stimulation, which boosts energy expenditure. These are still in development and not yet widely approved for obesity.

Web-based self-disclosure health support (WSHS) systems that incorporate forced self-disclosure and peer visibility of weight changes produce significantly greater short-term weight loss compared to standard one-on-one email health support.

To lose weight more effectively using digital tools, choose a platform that requires you to publicly share your progress (like weight and lifestyle) and view the progress of others, rather than just receiving private advice. The act of 'forced self-disclosure' and seeing peers' changes creates a social accountability loop that drives better results than private email counseling alone. Commit to weekly updates for 12 weeks.

Metformin is the preferred initial oral hypoglycemic agent for Type 2 Diabetes Mellitus due to its excellent blood glucose-lowering effect, relatively low side effects, long-term safety, low risk of hypoglycemia, and low weight gain.

Start metformin at a low dose and increase it slowly to minimize stomach upset. It is the standard first-line treatment because it lowers blood sugar effectively without causing significant weight gain or hypoglycemia.

DPP4 inhibitors are effective substitutes for metformin with low hypoglycemia risk, but their cardiovascular effects are neutral and they may slightly increase heart failure risk.

DPP4 inhibitors are a good option if metformin is not tolerated, offering low hypoglycemia risk. However, they do not provide cardiovascular benefits and may have a slight risk of heart failure.

Low intake of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) significantly amplifies the cardiovascular disease (CVD) risk associated with having a family history of CVD, whereas low intake of other polyunsaturated fatty acids (linoleic acid and alpha-linolenic acid) does not show this interaction.

If you have a family history of heart disease, your risk is significantly higher if your levels of EPA and DHA (found in oily fish) are low. While general healthy fats are good, ensuring adequate intake of EPA/DHA is specifically critical for you to mitigate this genetic risk. Aim to consume oily fish regularly to raise these biomarkers.

Physical activity alone is an effective strategy for reducing obesity and related comorbidities, particularly abdominal fat, even without dietary energy restriction.

To lose fat, you do not necessarily need to diet. Engaging in 45-60 minutes of moderate exercise daily is sufficient to reduce body mass and abdominal fat. Focus on consistency rather than extreme intensity if you are not restricting calories.

Exercise interventions typically result in less weight loss than predicted by simple energy balance models due to metabolic and behavioral compensation.

Do not be discouraged if you do not lose weight as fast as you calculate. Your body will try to compensate by making you hungrier or moving less. Focus on the health benefits and consistency rather than just the scale.

Bariatric surgery significantly reduces the incidence of new-onset type 2 diabetes, hypertension, and dyslipidemia in severely obese individuals compared to no intervention.

For severely obese individuals, bariatric surgery is a highly effective preventive measure against developing type 2 diabetes, high blood pressure, and high cholesterol. The study shows that surgery reduces the risk of developing these conditions by 55-94% compared to no treatment. This should be a key factor in treatment decisions for severe obesity, especially in regions with high metabolic disease rates.

Intensive lifestyle interventions (caloric restriction and physical activity) can induce significant weight loss (5-10%) and improve glycemic control in type 2 diabetes, but long-term maintenance is difficult due to physiological counter-regulation (increased appetite/hormonal resistance).

Start with lifestyle changes (diet and exercise) as they are the foundation of treatment. Aim for 5-10% weight loss to improve health. Be aware that your body will fight back with increased hunger after you lose weight. If you struggle to maintain weight loss long-term, consider adding medications that help counteract this hunger.

Insulin and Sulfonylureas cause weight gain in T2D patients, which exacerbates insulin resistance and creates a cycle requiring further treatment intensification.

Be aware that insulin and sulfonylureas can cause weight gain. If you are gaining weight on these medications, discuss alternatives with your doctor that do not cause weight gain.

Initiating combination therapy at the time of diagnosis for Type 2 Diabetes is scientifically supported to improve durability of glycaemic control and reduce complications, yet is underutilized due to 'clinical inertia'.

If your blood sugar is high at diagnosis, do not accept being put on just one medication if your doctor suggests it might not be enough. The paper argues that starting with a combination of drugs early on is scientifically better for long-term control and prevents complications. Ask your doctor why combination therapy isn't being used if your levels are high. Do not let 'clinical inertia' (delaying treatment) prevent you from getting the best possible control from the start.

A high carbohydrate-to-fat intake ratio (specifically high carbohydrate and low fat intake) is associated with lower long-term HDL-cholesterol levels and a significantly increased risk of incident hypo-HDL-cholesterolemia.

If you eat a diet very high in carbohydrates and very low in fat (like a traditional Korean diet heavy in white rice), your HDL 'good' cholesterol levels tend to be lower over time, and your risk of developing low HDL increases. To support healthy HDL levels, ensure your carbohydrate intake is balanced with adequate fat intake, rather than maximizing carbs while minimizing fat.

Bariatric surgery yields significantly higher rates of complete and prolonged diabetes remission compared to usual care (lifestyle and medication management).

For patients with Type 2 Diabetes, bariatric surgery is a more effective intervention for achieving remission than lifestyle changes and medications alone. While surgery carries risks and potential for relapse, the data shows it significantly outperforms standard care in both complete and prolonged remission rates. Patients should discuss their eligibility and specific surgical options (like RYGB or Sleeve Gastrectomy) with their healthcare provider, weighing the higher remission probability against surgical risks.

Bariatric surgery patients often have higher baseline HbA1c and require more insulin, yet still achieve higher remission rates than usual care patients.

Even if your diabetes is severe (high HbA1c) or you require insulin, bariatric surgery may still offer a chance for remission, potentially more so than lifestyle changes alone. Do not rule out surgery solely based on the severity of your diabetes or current medication use.

GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) and slow chronic kidney disease progression in Type 2 Diabetes, but evidence for improving heart failure outcomes is mixed or insufficient.

If you have Type 2 Diabetes and high heart risk or kidney issues, GLP-1 agonists (like Ozempic, Trulicity, or Victoza) are highly recommended to prevent heart attacks and protect kidneys. However, they are not currently proven to treat existing heart failure. If you struggle with injections, ask about oral semaglutide.

Physical activity attenuates the obesity-increasing genetic effects associated with the FTO locus by approximately 20-30%.

If you have a family history of obesity linked to the FTO gene, regular physical activity is not just beneficial—it is a critical counter-measure. Engaging in regular exercise can reduce the genetic impact on your BMI by 20-30%, proving that lifestyle choices actively modify genetic risk.

FTO gene variants interact with sweet beverage consumption and alcohol intake to influence obesity and blood pressure.

If you have the FTO gene variant, be particularly mindful of your intake of sweet beverages and alcohol, as these interact with your genetics to increase obesity and blood pressure risk.

Lifestyle-mediated weight loss interventions (diet and/or exercise) induce significant DNA methylation changes in blood leukocytes and adipose tissue, potentially serving as biomarkers for predicting individual response to therapy and reflecting systemic metabolic improvements.

Lifestyle changes like diet and exercise don't just change your weight; they change how your genes are expressed. This means your body's biological response to weight loss is unique and can potentially be predicted by looking at specific DNA markers before you start. Consistent lifestyle interventions can reverse obesity-associated epigenetic patterns.

Baseline DNA methylation levels can serve as prognostic biomarkers to predict which individuals will successfully lose weight in response to lifestyle interventions.

Your body's current epigenetic state might tell you how well you'll respond to a specific diet or exercise plan before you even start. This suggests a future where weight loss strategies are tailored based on your unique biological markers rather than just your current weight.

High-bar narrow stance squats increase knee extensor demand (greater knee contribution to total moment and higher vastus lateris activity) compared to low-bar wide stance squats.

If you want to prioritize your quads, use a high-bar narrow stance. If you want to prioritize your hips and glutes, switch to a low-bar wide stance. These technical changes directly shift the mechanical load to the target muscles.

GLP-1 receptor agonists reduce the risk of heart failure hospitalization, with the most significant relative risk reduction observed in patients with heart failure with preserved ejection fraction (HFpEF) who have obesity.

If you have heart failure with preserved ejection fraction (HFpEF) and are overweight or obese, GLP-1 medications like semaglutide or efpeglenatide may significantly reduce your risk of being hospitalized for heart failure. These drugs work by improving blood sugar, reducing weight, and lowering inflammation. While not yet a standard treatment for all heart failure, they are a promising option, especially for those with obesity.

Bile acids, particularly lithocholic acid and hyocholic acid, improve glucose tolerance by activating the GPCR GPBAR1 (TGR5) on enteroendocrine cells, leading to increased GLP-1 secretion and insulin release.

Bile acids play a crucial role in glucose regulation by activating the GPBAR1 receptor, which stimulates the release of GLP-1 and insulin. This effect is particularly pronounced after meals containing fats and cholesterol, as bile acid levels rise. Post-bariatric surgery patients often experience improved glucose tolerance due to increased circulating bile acids. Maintaining a healthy gut microbiome may also influence bile acid composition and effectiveness.